Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T; EUROFORS Investigators. Obermayer-Pietsch BM, et al. Among authors: farrerons j. J Bone Miner Res. 2008 Oct;23(10):1591-600. doi: 10.1359/jbmr.080506. J Bone Miner Res. 2008. PMID: 18505369 Free article. Clinical Trial.
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC. Eastell R, et al. Among authors: farrerons j. J Bone Miner Res. 2009 Apr;24(4):726-36. doi: 10.1359/jbmr.081215. J Bone Miner Res. 2009. PMID: 19049337 Free article. Clinical Trial.
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group. Blumsohn A, et al. Osteoporos Int. 2011 Jun;22(6):1935-46. doi: 10.1007/s00198-010-1379-y. Epub 2010 Oct 12. Osteoporos Int. 2011. PMID: 20938767 Free PMC article. Clinical Trial.
Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J. Recker RR, et al. Among authors: farrerons j. J Bone Miner Res. 2009 Aug;24(8):1358-68. doi: 10.1359/jbmr.090315. J Bone Miner Res. 2009. PMID: 19338452 Free article. Clinical Trial.
Risk factors for prediction of inadequate response to antiresorptives.
Díez-Pérez A, Olmos JM, Nogués X, Sosa M, Díaz-Curiel M, Pérez-Castrillón JL, Pérez-Cano R, Muñoz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, González-Macías J. Díez-Pérez A, et al. Among authors: farrerons j. J Bone Miner Res. 2012 Apr;27(4):817-24. doi: 10.1002/jbmr.1496. J Bone Miner Res. 2012. PMID: 22161773 Free article.
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, Gallagher JC, Farrerons J, Wang A, Franchimont N, San Martin J, Grauer A, McClung M. Boonen S, et al. Among authors: farrerons j. J Clin Endocrinol Metab. 2011 Jun;96(6):1727-36. doi: 10.1210/jc.2010-2784. Epub 2011 Mar 16. J Clin Endocrinol Metab. 2011. PMID: 21411557 Clinical Trial.
44 results